Phase 4
Completed N=35
Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults
Source: ClinicalTrials.gov NCT00183729 ↗Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Dec 2016
Primary outcomePrimary: Depressive Symptoms — 12.5; 13.4; 7; 5.2 units on a scale — p=0.42
◆ Published Evidence
Established
64citations · ~5 / year
Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.
Summary
This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or cardiopulmonary condition.
Linked Publications
-
Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Depressive Symptoms |
12.5; 13.4; 7; 5.2 | 0.42 |
| SECONDARY Incidence of Major Depressive Disorder |
3; 1 | — |
| SECONDARY Functional Recovery |
73; 81 | 0.06 |
Eligibility Criteria
Inclusion Criteria
- Admission to a skilled nursing facility for rehabilitation within 3 months of recent disabling medical event (e.g., hip fracture)
- Medically stable (e.g., no active seizures, delirium, unstable pulse/blood pressure)
Exclusion Criteria
- Aphasia or cognitive impairments sufficiently severe to prevent valid assessment (e.g., a score of less than 22 on the Mini Mental State Examination)
- Current major depressive episode
- History of or current psychosis or mania
- Current substance or alcohol abuse or dependence (within 3 months of study entry)
- Current use of memantine
- Sensitivity or contraindication to memantine
- End-stage kidney, liver, heart, or lung disease
- Recent hemorrhagic stroke
- A FIM score of greater than 70 (on a 91 point scale)
Data sourced from ClinicalTrials.gov (NCT00183729) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.